Humacyte, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
HUMA Nasdaq 2836 www.humacyte.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Humacyte, Inc.

Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access - May 26th, 2026 6:00 am
Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs - May 20th, 2026 6:00 am
Why Humacyte, Inc. (HUMA) Price Target Was Raised Despite Early-Stage Commercialization - May 19th, 2026 5:08 am
Humacyte Inc (HUMA) Q1 2026 Earnings Call Highlights: Sales Surge and Strategic Expansions Amid ... - May 13th, 2026 5:02 pm
Humacyte (HUMA) Q1 2026 Earnings Transcript - May 13th, 2026 12:53 pm
Humacyte Q1 Earnings Call Highlights - May 13th, 2026 8:07 am
Humacyte Reports Q1 2026 Results: Full Earnings Call Transcript - May 13th, 2026 7:29 am
Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates - May 13th, 2026 6:35 am
Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update - May 13th, 2026 5:00 am
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates - May 12th, 2026 3:40 pm
Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer - May 12th, 2026 6:00 am
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why - May 8th, 2026 4:00 pm
Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026 - May 8th, 2026 6:00 am
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates - May 7th, 2026 9:15 am
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates - May 6th, 2026 4:30 pm
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains? - May 5th, 2026 7:12 am
A Look At Fresenius Medical Care (XTRA:FME) Valuation After The Symvess Distribution Agreement Revision - May 3rd, 2026 5:07 pm
Fresenius Medical Care’s Symvess Deal Shift And What It Means For Valuation - May 3rd, 2026 12:04 pm
Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth Knowing - Apr 30th, 2026 4:00 pm
Humacyte Highlights Dialysis Access Data; Women Show Strong ATEV Edge, V012 Results Due in June - Apr 28th, 2026 11:22 pm